New Digital Badge Recognizes Age-Friendly Pharmacists Committed to Improving Care for Older Adults and Lives of Caregivers
Offered by the American Society of Consultant Pharmacists in partnership with the Lamy Center at the University of Maryland School of Pharmacy
ALEXANDRIA, VIRGINIA / ACCESS Newswire / March 18, 2025 / (March 17, 2025 - Alexandria, VA) The American Society of Consultant Pharmacists (ASCP) and The Peter Lamy Center on Drug Therapy and Aging (Lamy Center) at the University of Maryland School of Pharmacy now offer a digital badge to pharmacists who have demonstrated an understanding and application of the elements of the Age-Friendly Health Systems movement. The 'Age-Friendly Pharmacist' digital badge recognizes pharmacists who have completed training modules on the Age-Friendly 4Ms Framework (What Matters, Medication, Mentation, and Mobility) and made a commitment to improving the health and well-being of older adults.
'Pharmacists are one of the most accessible health care practitioners, and they are perfectly positioned to help older adults gain the most benefit from Age-Friendly care,' said Lamy Center Executive Director Nicole J. Brandt, PharmD, MBA. 'Our program leverages the role pharmacists play in healthy aging and transforming long-term care settings into Age-Friendly Health Systems.' An initiative of The John A. Hartford Foundation and the Institute for Healthcare Improvement, Age-Friendly Health Systems is a movement to help spread the reliable delivery of health care that addresses the unique needs of older adults and enables them to enjoy a better quality of life.
'We believe the 'Age-Friendly Pharmacist' digital badge will validate the skills and elevate the profile of pharmacists practicing the 4Ms of age-friendly care,' said ASCP Chief Executive Chad Worz, PharmD. 'The digital badge identifies the pharmacist as a healthy aging expert, serves as proof of competence, and rewards skills development and lifelong learning.' To be awarded a digital badge, pharmacists must complete three steps consisting of education and training on becoming age-friendly pharmacists, understanding/implementing the 4Ms Framework, and advancing age-friendly care. After completing a final survey, eligible pharmacists will earn a digital badge and can showcase their skills and achievement with the digital badge through social media pages and online profiles.
The badge is verified through the Credly digital credentialling platform and offered through the 'Leveraging Pharmacists as Age-Friendly 4Ms Champions' program funded by The John A. Hartford Foundation. To learn more about the 'Age-Friendly Pharmacist' digital badge and this pharmacist-led initiative, visit Age-Friendly Pharmacists. (www.ascp.com/page/agefriendly, #Pharmacist4Ms)
ABOUT US
American Society of Consultant Pharmacists (ASCP) is the only international professional society devoted to optimal medication management and improved health outcomes for all older people. ASCP's members manage and improve drug therapy and improve the quality of life of geriatric patients and other individuals residing in nursing facilities, sub-acute care and assisted living facilities, psychiatric hospitals, hospice programs, and home and community-based care environments. ( https://www.ascp.com/page/about)
The Peter Lamy Center on Drug Therapy and Aging (Lamy Center) is dedicated to improving drug therapy for aging adults through innovative research, education, and clinical initiatives. The Lamy Center's mission is to improve the lives of older adults by optimizing medication safety and use. ( https://www.pharmacy.umaryland.edu/centers/lamy/)
The University of Maryland School of Pharmacy was established in 1841 and is ranked 15th out of more than 140 schools of pharmacy by U.S. News & World Report. The School is a thriving center for professional and graduate education, pharmaceutical care, research, and community service. Its faculty create the future of pharmacy by pioneering new roles for pharmacists in advanced clinical practice and conducting cutting-edge research in drug discovery and development, comparative effectiveness and patient-centered outcomes, and disease management. ( https://www.pharmacy.umaryland.edu/about/)
ASCP Foundation is a 501(c)(3) charitable organization established in 1982. The mission of the ASCP Foundation is to carry out the charitable - including scientific, literary, and educational - purposes of ASCP. ( https://www.ascp.com/page/foundation)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
4 days ago
- Business Wire
Alto Neuroscience Presents Data at the 2025 American Society of Clinical Psychopharmacology Annual Meeting Reinforcing Safety and Tolerability Profile for ALTO-300 in Major Depressive Disorder
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. ('Alto') (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced a presentation at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, in Scottsdale, Arizona, held May 27-30, 2025. ALTO-300, also known as agomelatine, is an oral, small molecule designed to act as a melatonin agonist and 5-HT2C antagonist being developed at 25mg as an adjunctive treatment in the United States for patients with MDD, characterized by an EEG biomarker. Agomelatine is an approved antidepressant medication at both 25mg and 50mg in Europe and Australia but has not been approved in the United States. In clinical studies, the 50mg dose of agomelatine was associated with low levels of reversible liver enzyme elevations, which were not associated with liver failure. In comparison to the 50mg dose of agomelatine, the 25mg dose has been shown to have similar antidepressant activity while avoiding the rates of liver function test (LFT) elevations associated with the 50mg dose. 'Our ASCP presentation continues to support the unique biomarker opportunity for patient stratification and reinforces the well-established safety and tolerability profile for ALTO-300,' said Amit Etkin, M.D., Ph.D., founder and chief executive officer of Alto Neuroscience. 'Agomelatine has been studied in thousands of patients globally and evidence from meta-analyses and real-world clinical care demonstrates the 25mg dose achieves an optimal balance of antidepressant activity without the concern of LFT elevation. These data are consistent with the positive results from our completed Phase 2a trial, and we are encouraged by the safety and tolerability profile of ALTO-300 in our ongoing Phase 2b trial in patients with major depressive disorder. Taken together, we believe the selected 25mg dose of ALTO-300 is well positioned to demonstrate clinical effects while avoiding the low LFT elevation rates associated with the 50mg dose, which typically occur early, are non-cumulative, resolve quickly, and are not associated with liver failure.' Summary of Data Presented ALTO-300 Safety and Tolerability Profile The most common adverse event observed in the completed Phase 2a trial of ALTO-300 was headache. Additionally, the Phase 2a and Phase 2b trials have involved monitoring for elevated liver enzymes (≥ 3 times the upper limit of normal), with the Phase 2b trial including a stopping rule for elevated liver enzymes. No LFT elevations ≥ 3 times the upper limit of normal were observed in the Company's 239-patient completed Phase 2a trial, and no patients have been stopped in the ongoing Phase 2b trial due to liver enzyme elevation, which remains blinded. ALTO-300 EEG Biomarker The ALTO-300 biomarker signal likely reflects increased neural noise due to elevated 5-HT2C tone and reduced dopaminergic activity. Increasing 5-HT2C activity in a preclinical rodent model or directly depleting dopamine in a healthy human volunteer study—both the oppositive mechanistic effect of ALTO-300—resulted in greater EEG irregularity, consistent with a biomarker positive profile. These data reinforce the direct link between ALTO-300 and the EEG biomarker used to identify MDD patients who are more likely to be responders to treatment. The following poster presented at ASCP 2025 is available under ' Publications ' in the platform section of Alto's website: ALTO-300 as Adjunctive Treatment for Major Depressive Disorder Supported by Mechanistic Validation of Patient Selection Biomarker and Well-Established Safety and Tolerability Profile Poster First Author: Michael Avissar, Ph.D. About Alto Neuroscience Alto Neuroscience is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options. Alto's Precision Psychiatry Platform™ measures brain biomarkers by analyzing EEG activity, neurocognitive assessments, wearable data, and other factors to better identify which patients are more likely to respond to Alto product candidates. Alto's clinical-stage pipeline includes novel drug candidates in bipolar depression, major depressive disorder, schizophrenia, and other mental health conditions. For more information, visit or follow Alto on X. Forward-Looking Statements This press release may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as 'expects,' 'plans,' 'will' and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding Alto's expectations about the potential benefits, activity, and effectiveness of its product candidates, biomarkers, and Precision Psychiatry Platform ('Platform'); and Alto's expectations with regard to the design and results of its clinical trials. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including uncertainties inherent in the initiation, progress and completion of clinical trials and other important factors, any of which could cause Alto's actual results to differ from those contained in the forward-looking statements, which are described in greater detail in the section titled 'Risk Factors' in Alto's Annual Report on Form 10-K for the fiscal year ended December 31, 2024 filed with the Securities and Exchange Commission ('SEC') as well as in other filings Alto may make with the SEC in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and Alto expressly disclaims any obligation to update any forward-looking statements contained herein, whether because of any new information, future events, changed circumstances or otherwise, except as required by law. Availability of Information on Alto's Website Alto routinely uses its investor relations website to post presentations to investors and other important information, including information that may be material. Accordingly, Alto encourages investors and others interested in Alto to review the information it makes public on its investor relations website.
Yahoo
5 days ago
- Yahoo
Ancient bread rises again as Turkey recreates 5,000-year-old loaf
In the early Bronze Age, a piece of bread was buried beneath the threshold of a newly built house in what is today central Turkey. Now, more than 5,000 years later, archaeologists have unearthed it, and helped a local bakery to recreate the recipe -- with customers lining up to buy it. Round and flat like a pancake, 12 centimetres (five inches) in diameter, the bread was discovered during excavations at Kulluoba, a site near the central Anatolian city of Eskisehir. "This is the oldest baked bread to have come to light during an excavation, and it has largely been able to preserve its shape," said Murat Turkteki, archaeologist and director of the excavation. "Bread is a rare find during an excavation. Usually, you only find crumbs," he told AFP. "But here, it was preserved because it had been burnt and buried," he said. The bread was charred and buried under the entrance of a dwelling built around 3,300 BC. A piece had been torn off, before the bread was burnt, then buried when the house was built. "It makes us think of a ritual of abundance," Turkteki said. - 'Moved by this discovery' - Unearthed in September 2024, the charred bread has been on display at the Eskisehir Archaeological Museum since Wednesday. "We were very moved by this discovery. Talking to our excavation director, I wondered if we could reproduce this bread," said the city's mayor, Ayse Unluce. Analyses showed that the bread was made with coarsely ground emmer flour, an ancient variety of wheat, and lentil seeds, with the leaf of an as yet undetermined plant used as yeast. Ancient emmer seeds no longer exist in Turkey. To get as close as possible to the original recipe, the municipality, after analysing the ancient bread, decided to use Kavilca wheat, a variety that is close to ancient emmer, as well as bulgur and lentils. At the Halk Ekmek bakery (meaning "People's Bread" in Turkish), promoted by the municipality to offer low-cost bread, employees have been shaping 300 loaves of Kulluoba by hand every day. "The combination of ancestral wheat flour, lentils and bulgur results in a rich, satiating, low-gluten, preservative-free bread," said Serap Guler, the bakery's manager. The first Kulluoba loaves, marketed as 300-gramme (11-ounce) cakes that cost 50 Turkish lira (around $1.28), sold out within hours. "I rushed because I was afraid there wouldn't be any left. I'm curious about the taste of this ancient bread," said customer Suzan Kuru. - Drought resistant - In the absence of written traces, the civilisation of Kulluoba remains largely mysterious. In the Bronze Age, the Hattians, an Anatolian people who preceded the Hittites, lived in the Eskisehir region. "Kulluoba was a medium-sized urban agglomeration engaged in commercial activities, crafts, agriculture and mining. There was clearly a certain family and social order," said archaeologist Deniz Sari. The rediscovery of the bread has sparked interest in the cultivation of ancient wheats better adapted to drought. Once rich in water sources, the province of Eskisehir is today suffering from drought. "We're facing a climate crisis, but we're still growing corn and sunflowers, which require a lot of water," said Unluce, the local mayor. "Our ancestors are teaching us a lesson. Like them, we should be moving towards less thirsty crops," she added. The mayor wants to revive the cultivation of Kavilca wheat in the region, which is resistant to drought and disease. "We need strong policies on this subject. Cultivating ancient wheat will be a symbolic step in this direction," she said. "These lands have preserved this bread for 5,000 years and given us this gift. We have a duty to protect this heritage and pass it on." bg/rba/ach/fo/jhb
Yahoo
6 days ago
- Yahoo
Neuphoria to Present at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting
BURLINGTON, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (Nasdaq: NEUP) ('Neuphoria' or the 'Company'), a clinical-stage biotechnology company developing impactful treatments for neuropsychiatric disorders, today announced an upcoming presentation at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting. Presentation details: Title: Pharmacokinetic/Pharmacodynamic Analysis of the BNC210 Attune Phase 2b Dataset Enables Dose Selection for Planned Phase 3 PTSD Study Presenter: Spyros Papapetropoulos, M.D., Ph.D., Neuphoria President and CEO Type: Oral presentation Location: ASCP 2025 Annual Meeting, Fairmont Scottsdale Princess Salon Ballroom H, Scottsdale, AZ Session: Individual research reports Date: Wednesday, 28th May, 2025 Time: 3:40-4:00 pm MST FOR FURTHER INFORMATION PLEASE CONTACT: GeneralSpyridon (Spyros) Papapetropoulosinfo@ Investor RelationsKevin Gardnerkgardner@ About Neuphoria Therapeutics (Nasdaq: NEUP) is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. Neuphoria is advancing its lead drug candidate, BNC210, an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute, 'as needed' treatment of social anxiety disorder (SAD) and for chronic treatment of post-traumatic stress disorder (PTSD). BNC210 is a first-of-its-kind, well-tolerated, broad spectrum anti-anxiety experimental therapeutic, designed to restore neurotransmitter balance in relevant brain areas, providing rapid relief from stress and anxiety symptoms without the common pitfalls of sedation, cognitive impairment, or addiction. In addition, Neuphoria has a strategic partnership with Merck & Co., Inc. (known as MSD outside the United States and Canada) with two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer's disease and other central nervous system conditions. Neuphoria's pipeline also includes the α7 nicotinic acetylcholine receptor next generation and the Kv3.1/3.2 preclinical programs, both in the lead optimization development stage. Forward-Looking StatementsNeuphoria cautions that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as 'may,' 'could,' 'will,' 'would,' 'should,' 'expect,' 'plan,' 'anticipate,' 'believe,' 'estimate,' 'intend,' 'predict,' 'seek,' 'contemplate,' 'potential,' 'continue' or 'project' or the negative of these terms or other comparable terminology are intended to identify forward-looking statements. The forward-looking statements are based on our current beliefs, plans, burn rate and expectations. Certain forward-looking statements, including (without limitation) about (1) Neuphoria's ability to develop and expand its business, successfully complete development of its current product candidates, the timing of commencement and/or completion of various clinical trials and receipt of data and current and future collaborations for the development and commercialization of its product candidates, (2) the market for drugs to treat CNS diseases and pain conditions, (3) Neuphoria's financial resources, and (4) assumptions underlying any such statements. The inclusion of forward-looking statements should not be regarded as a representation by Neuphoria that any of its plans will be achieved. Future events and actual results could differ materially from those set out in, contemplated by or underlying the forward-looking statements due to a number of important factors. Certain forward-looking statements involve contracts, licenses and arrangements involving third parties and their respective clinical trial and research and development projects that are out of our control, including our agreements with Merck and Carina. They may terminate or delay any or all such projects in their discretion pursuant to the terms of our agreements with them, which could result in the Company not realizing any further milestone payments or further progress on the respective product pathways. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the Company's business and other risks described in the Company's filings with the SEC, including the Company's Annual Report on Form 10-K, Quarterly Report on Form 10-Q, each filed with the SEC, and its other reports. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Neuphoria undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. Further information regarding these and other risks, uncertainties and other factors is included in Neuphoria's filings with the SEC, copies of which are available from the SEC's website ( and on Neuphoria's website ( under the heading 'Investor Center.' All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995. Neuphoria expressly disclaims all liability in respect to actions taken or not taken based on any or all the contents of this press release.
